Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab plus IVIG for Acute Kawasaki Disease
NCT00760435Phase 3Completed
- Sponsor
- University of California, San Diego
- Start
- Mar 2009
- Primary completion
- Oct 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Kawasaki disease (KD) comparing Infliximab plus IVIG with Placebo plus IVIG (2 arms). Primary endpoint: Number of Subjects in Each Arm That Have Persistent or Recrudescent Fever 24 Hours After Completion of the Intravenous Immunoglobulin (IVIG) Infusion at 10 weeks. Started Mar 2009; status: completed.
02
Drugs
infliximab
03
Conditions
Kawasaki disease (KD)
Beyond the preview
Go deeper on NCT00760435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00760435.